Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 plus trastuzumab and XELOX versus placebo plus trastuzumab and XELOX as first-line treatment for HER2-positive advanced or metastatic gastric cancer
CTR20211256Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by HyBioPharma. Started Sep 2021; status: active.
02
Drugs
hlx22
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20211256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211256.